内皮素受体阻滞剂的合成研究进展  

Progress in the synthesis of endothelin receptor antagonists

作　　者：董俊军[1] 杨宁[1] 刘克良[1] 

机构地区：[1]军事医学科学院毒物药物研究所,北京100850

出　　处：《中国新药杂志》2004年第8期680-684,共5页Chinese Journal of New Drugs

基　　金：国家高技术研究发展计划(863)重点项目(2001AA235021)

摘　　要：内皮素具有很强的缩血管作用,与受体结合可产生广泛的生物学效应,它参与了多种心脑血管疾病的发生和发展过程,研究其受体阻滞剂具有重要意义。现综述了不同结构内皮素受体阻滞剂合成研究的进展,供该类新药的合成研发参考。Endothelin (ET) is one of the most potent vasoconstrictor peptides. The interaction of ET with its receptor plays an important role in the pathological process responsible for varieties of cardiovascular (CV) and cerebrovascular (CB) diseases.Therefore.it is important to investigate antagonists to the ET receptor that is likely to have a benefit in the prevention and treatment of the CV and CB diseases. The recent progresses in the synthesis of different types of ET receptor antagonists were reviewed in this paper.

关 键 词：内皮素 内皮素受体阻滞剂 药物合成 

分 类 号：R914.5[医药卫生—药物化学] R972.4[医药卫生—药学]